Evidence map›Paper›PMID 35584239›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition.

John D Martin, Ryan M Lanning, Vikash P Chauhan, Margaret R Martin, Ahmed S Mousa, Walid S Kamoun, Hee-Sun Han, Hang Lee, Triantafyllos Stylianopoulos, Moungi G Bawendi and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment.Frontiers in cell and developmental biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

John D Martin *Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9828-8203
Ryan M Lanning *Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9267-519X
Vikash P ChauhanEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Margaret R MartinEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Ahmed S MousaEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Walid S KamounEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Hee-Sun HanDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts.ORCID 0000-0003-3616-291X
Hang LeeBiostatistics Center, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts.
Triantafyllos StylianopoulosEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Moungi G BawendiDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Dan G DudaEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7065-8797
Edward B BrownEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Timothy P PaderaEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-3453-9384
Dai FukumuraEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9505-4444
Rakesh K JainEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7571-3548
Massachusetts General Hospital · USMassachusetts Institute of Technology · USHarvard University · US

Funding

Vascular Normalization: Rolse of Perivascular CellsP01CA080124 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI · 2000 to 2016
$35.0M
Dissecting Pediatric Brain Tumor Microenvironment to Improve TreatmentR35CA197743 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2015 to 2020
$5.7M
Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistanceU01CA261842 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., MUNN, LANCE L. · 2021 to 2025
$3.1M
A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC PatientsR01CA260872 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AMIN, HESHAM M, DUDA, DAN GABRIEL · 2021 to 2025
$3.0M
Reprogramming PDAC tumor microenvironment to improve immunotherapyU01CA224348 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BOUCHER, YVES, JAIN, RAKESH K. · 2017 to 2021
$2.9M
Systems biology of lymphatic transportR01HL128168 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MUNN, LANCE L., PADERA, TIMOTHY P · 2015 to 2019
$2.9M
Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapyR01CA260857 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Dan Gabriel Duda, Anand T.N. Kumar · 2021 to 2026
$2.7M
Improving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolismR01CA259253 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., VANDER HEIDEN, MATTHEW G. · 2021 to 2025
$2.3M
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatmentR01CA208205 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI, JAIN, RAKESH K. · 2017 to 2020
$2.2M
Targeting lymph node metastases to prevent cancer progressionR01CA214913 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PADERA, TIMOTHY P · 2017 to 2022
$2.0M
Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2R01NS118929 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI · 2021 to 2025
$2.0M
Reprogramming the tumormicroenvironment to improve immunotherapy of glioblastomaR01CA269672 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Rakesh K. Jain · 2022 to 2026
$1.9M
NCI NIH HHS P01 CA080124NCI NIH HHS R01 CA194535NCI NIH HHS R01 CA208205NCI NIH HHS R01 CA214913NCI NIH HHS R01 CA247441NCI NIH HHS R01 CA259253NCI NIH HHS R01 CA260857NCI NIH HHS R01 CA260872NCI NIH HHS R01 CA269672NCI NIH HHS R03 CA256764NCI NIH HHS R35 CA197743NCI NIH HHS U01 CA224348NCI NIH HHS U01 CA261842NHLBI NIH HHS R01 HL128168NIAID NIH HHS R21 AI135092NIA NIH HHS R21 AG072205NINDS NIH HHS R01 NS118929
6 · The paper itself

Abstract

purposeThe abnormal function of tumor blood vessels causes tissue hypoxia, promoting disease progression and treatment resistance. Although tumor microenvironment normalization strategies can alleviate hypoxia globally, how local oxygen levels change is not known because of the inability to longitudinally assess vascular and interstitial oxygen in tumors with sufficient resolution. Understanding the spatial and temporal heterogeneity should help improve the outcome of various normalization strategies. EXPERIMENTAL

designWe developed a multiphoton phosphorescence quenching microscopy system using a low-molecular-weight palladium porphyrin probe to measure perfused vessels, oxygen tension, and their spatial correlations in vivo in mouse skin, bone marrow, and four different tumor models. Further, we measured the temporal and spatial changes in oxygen and vessel perfusion in tumors in response to an anti-VEGFR2 antibody (DC101) and an angiotensin-receptor blocker (losartan).

resultsWe found that vessel function was highly dependent on tumor type. Although some tumors had vessels with greater oxygen-carrying ability than those of normal skin, most tumors had inefficient vessels. Further, intervessel heterogeneity in tumors is associated with heterogeneous response to DC101 and losartan. Using both vascular and stromal normalizing agents, we show that spatial heterogeneity in oxygen levels persists, even with reductions in mean extravascular hypoxia.

conclusionsHigh-resolution spatial and temporal responses of tumor vessels to two agents known to improve vascular perfusion globally reveal spatially heterogeneous changes in vessel structure and function. These dynamic vascular changes should be considered in optimizing the dose and schedule of vascular and stromal normalizing strategies to improve the therapeutic outcome.

Indexed as

MicroscopyNeoplasmsAngiotensinsAnimalsHypoxiaLosartanMiceOxygenReceptors, AngiotensinTumor MicroenvironmentAngiotensinsLosartanOxygenReceptors, Angiotensin

Identifiers

PMID35584239
PMCPMC9355624
OpenAlexW4280522200

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.